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Summary 
Limb-girdle muscular dystrophies (LGMDs) are a group 
of inherited diseases whose genetic etiology has yet to 
be elucidated. The autosomal recessive forms (LGMD2) 
constitute a genetically heterogeneous group with 
LGMD2A mapping to chromosome 15q15.1-q21.1. The 
gene encoding the muscle-specific calcium-activated 
neutral protease 3 (CANP3) large subunit is located 
in this region. This cysteine protease belongs to the 
family of intracellular calpains. Fifteen nonsense, 
splice site, frameshift, or missense calpain mutations 
cosegregate with the disease in LGMD2A families, six 
of which were found within La Rdunion island patients. 
A digenic inheritance model is proposed to account 
for the unexpected presence of multiple independent 
mutations in this small inbred population. Finally, 
these results demonstrate an enzymatic rather than a 
structural protein defect causing a muscular dystro- 
phy, a defect that may have regulatory consequences, 
perhaps in signal transduction. 
Introduction 
The term limb-girdle muscular dystrophy (LGMD) was first 
proposed by Walton and Nattrass (1954) as part of a classi- 
fication of muscular dystrophies. LGMD is characterized 
by progressive symmetrical atrophy and weakness of the 
proximal limb muscles and elevated serum creatine ki- 
nase. The symptoms usually begin during the first two 
decades of life, and the disease gradually worsens, often 
resulting in loss of walking ability 10 or 20 years after onset 
(Bushby, 1994). Yet the precise nosological definition of 
LGMD still remains unclear. Consequently, various neuro- 
muscular diseases such as facioscapulohumeral, Becker 
muscular dystrophies, and especially spinal muscular at- 
rophies have occasionally been classified under this diag- 
nosis. These issues highlight he difficulty in undertaking 
an analysis of the molecular and genetic defect(s) involved 
in this pathology. 
Both autosomal dominant and recessive transmission 
have been reported, the latter being more common with 
an estimated prevalence of 10 -5 (Emery, 1991). The local- 
ization of a gene on chromosome 15 (LGMD2A, MIM 
253600; Beckmann et al., 1991) has provided proof for 
the genetic basis of one form of recessive LGMDs. Subse- 
quent genetic analyses confirmed this chromosome 15 
localization (Young et al., 1992; Passos-Bueno et al., 
1993). The latter group also demonstrated genetic hetero- 
geneity of this disease, while a recent study localized the 
LGMD2B gene to chromosome 2 (Bashir et al., 1994). Yet 
there is evidence that at least one other locus is involved, 
since genetic heterogeneity was demonstrated in the in- 
bred Indiana Amish LGMD2 kindreds (Allamand et al., 
1995a). 
The nonspecific nosological definition, the relatively low 
prevalence, and genetic heterogeneity of this disorder limit 
the number of families that can be used to restrict the 
genetic boundaries of the LGMD2A interval. No cytoge- 
netic abnormalities have been reported. Immunogenetic 
studies of the dystrophin-associated protein complex (Mat- 
sumara et al., 1993) and cytoskeletal or extracellular ma- 
trix proteins (e.g., Tom~ et al., 1994) failed to demonstrate 
any deficiency, in addition, there is no known specific 
physiological feature or animal model to suggest a candi- 
date gene. Thus, there was no alternative to a positional 
cloning strategy. 
Detailed genetic and physical maps of the 15q15.1- 
q21.1 LGMD2A region were established. Construction and 
analysis of a 10-12 Mb yeast artificial chromosome (YAC) 
contig (Fougerousse et al., 1994) permitted the mapping 
of 33 polymorphic markers within this interval and to nar- 
row the LGMD2A region to between D15S514 and D15S222. 
Furthermore, extensive analysis of linkage disequilibrium 
suggested a likely position for the gene in the proximal 
part of the contig (Allamand et al., 1995b). 
cDNA selection (Tagie et al., 1993) for muscle-expressed 
sequences encoded by this interval led to the identification 
of five known genes and 10 newly expressed sequences, 
Cell 
28 
Table 1. PCR Primers for the Localization of the CANP3 Gone 
PCR Product Size (Base Pairs) 
Position within 
Primer Name Primer Sequence (5'-3') the cDNA cDNA Genomic DNA 
Annealing 
Temperature 
(in Celsius) 
CANP3-in2.a ATGGAGCCAACAGAACTGAC 341-360 108 1758 
CANP3-in2.m GTATGACTCGGAAAAGAAGGT 428-448 
CANP3-inl 3.a TAAGCAAAAGCAGTCCCCAC 1893-1912 64 1043 
CAN P3qnl 3.m TTGCTGTTCCTCACTTTCCTG 1936-1956 
CAN P3-6a3.a GTTTCATCTGCTGCTTCGTT 2342-2361 130 818 
CANP3-6a3.m CTGGTTCAGGCATACATGGT 2452-2471 
CANP3-exlter.a TTCTTTATGTGGACCCTGAGTT 218-239 76 76 
CANP3-exlter.m ACGAACTGGATGGGGAACT 275-293 
58 
58 
56 
55 
all potential candidate genes (Chiannilkulchai et al., 1995). 
One of these, previously cloned by Sorimachi et al. (1989), 
appeared also to be a functional candidate gone, as it 
encodes a muscle-specific protein, CANP3 (named for cal- 
pain large polypeptide L3), which belongs to the calpain 
family (or calcium-activated neutral protease [CANP]; EC 
3.4.22.17). 
Calpains are nonlysosomal intracellular cysteine prote- 
ases (Murachi, 1989; Suzuki and Ohno, 1990; Croall and 
Demartino, 1991). The mammalian calpains include two 
ubiquitous proteins, CANP1 and CANP2, as well as two 
stomach-specific proteins (Sorimachi et al., 1993a) and 
CANP3. The ubiquitous enzymes consist of heterodimers 
with distinct large subunits associated with a common 
small subunit (Murachi, 1989), all of which are encoded 
by different genes (Ohno et al., 1989). The association of 
tissue-specific large subunits with a small subunit has not 
yet been demonstrated. The large subunits of calpains 
can be subdivided into four domains (Ohno et al., 1984). 
Domains I and III, whose functions remain unknown, show 
no homology with known proteins. The former, however, 
might be important for the regulation of the proteolytic 
activity (Imajoh et al., 1986). Domain II shows similarity 
with other cysteine proteases, which share histidine, cys- 
teine, and asparagine residues at their active sites (Sori- 
machi et al., 1989). Domain IV comprises four EF hand 
structures that are potential calcium-binding sites. In addi- 
tion, three unique regions with no known homology are 
present in the muscle-specific CANP3 protein, namely NS, 
IS1, and IS2, the latter containing a nuclear translocation 
signal (Sorimachi et al., 1989). These regions may be im- 
portant for the muscle-specific function of CANP3. 
We have determined the genomic organization of the 
human CANP3 gene, which consists of 24 exons and ex- 
tends over 40 kb, 35 kb of which have been sequenced. 
A systematic screening of this gone in LGMD families led 
to the identification of 15 different mutations, establishing 
that mutational events in CANP3 are responsible for 
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Figure 1. GenomicOrganizationoftheCANP3 
Gone 
(A) The CANP3 gone covers a 40 kb region 
of which 35 kb were sequenced. Introns and 
exons are drawn to scale, exons being indi- 
cated by numbered vertical bars. Intron 1 is the 
largest one and remains to be fully sequenced 
as well as intron 8. Positions of intragenic mi- 
crosatellites are indicated by asterisks. Closed 
and cross-hatched arrows indicate the orienta- 
tion of Alu and MER2 repeat sequences, re- 
spectively. 
(B) EcoRI restriction map. An EcoRI (E) restric- 
tion map was established with cosmids from 
this region. The location of the CANP3 gone 
is indicated by a closed bar. The size of the 
corresponding fragments are indicated and 
underlined when determined by sequence 
analysis. 
(C) Cosmid map of the CANP3 gone region. 
Cosmids, from a library constructed by sub- 
cloning YAC 774G4, are presented as lines. 
Overlaps are based on sequence-tagged site 
information from a cosmid contig established 
by I. R. et al. (unpublished ata). Dots on lines 
indicate positive sequence-tagged sites, which 
are boxed in rectangles. A minimum of three 
cosmids covers the entire gone. 
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Figure 2. Sequence of the Human CANP3 cDNA and Flanking 5' and 
3' Genomic Regions 
(A) and (C) show the polyadenylation signal and putative CAAT and 
TATAA sites, which are boxed. The putative Spl (position -477 to 
-472), MAF2-binding sites (position -364 to -343), and CArG box 
(position -685 to -672) are in bold. The Alu sequence present in the 
5' region is underlined. (B) shows the corresponding amino acids, 
indicated below the sequence. The coding sequence between the ATG 
initiation codon and the TGA stop codon is 2466 bp, encoding for an 
821 amino acid protein. The adenine in the first methionine codon has 
been assigned position 1. Locations of introns within the CANP3 gene 
are indicated by arrowheads. Nucleotides that differ from the pre- 
viously published ones are indicated by asterisks. 
LGMD2A. Finally, this demonstrates a case of muscular 
dystrophy resulting from an enzymatic rather than a struc- 
tural defect. 
Results 
Localization of CANP3 within the LGMD2A Interval 
cDNA capture using YACs from the LGMD2A interval al- 
lowed the identification of 15 positional candidate genes. 
CANP3 was one of two transcripts that showed muscle- 
specific expression as evidenced by Northern blot analysis 
(Chiannilkulchai et al., 1995). The CANP3 gene had pre- 
viously been localized to chromosome 15 (Ohno et al., 
1989). Primers (Table 1 ; Figure 1) designed from different 
parts of the published human cDNA sequence (Sorimachi 
et al., 1989) were used to position the gene in a region 
previously defined as 15q15.1-q21.1 (Richard et al., 1994) 
and, more precisely, on three YACs (774G4, 926G10, and 
923G7) localized in this region, between D15S512 and 
D15S488, in a candidate region suggested by linkage dis- 
equilibrium studies (Allamand et al., 1995b). 
These primers were also used to screen a cosmid library 
derived from YAC 774G4 (I, R. et al., unpublished data). 
Five cosmids were identified. Experiments with different 
primer pairs (Table 1) established that these cosmids 
cover all CANP3 exons except exon 1 and that a second 
group of four cosmids contain this exon (Figure 1C). A 
minimal set of three overlapping cosmids (2G8-2B11-  
1F l l )  covers the entire gene. DNA from these cosmids 
was used to construct an EcoRI restriction map of this 
region (Figure 1B). 
The CANP3 Gene Sequence 
Most of the sequences were obtained through shotgun 
sequencing of partial digests of cosmid 1F l l  subcloned 
in M13 and Bluescript vectors and by walking with internal 
primers. The sequence assembly was in agreement with 
the restriction map of the cosmids. Sequences of exon 1 
and adjacent regions were obtained by sequencing cos- 
mid DNA or polymerase chain reaction (PCR) products 
from human genomic DNA. The first and eighth introns 
are still not fully sequenced, but there is evidence that 
they may be between 10 and 16 kb and about 2 kb in 
length, respectively (based on hybridization of restriction 
fragments; data not shown). The entire gene spans more 
than 40 kb. 
The determined CANP3 sequence completes the pub- 
lished human cDNA sequence (Sorimachi et al., 1989). 
It contains the missing 129 bases corresponding to the 
N-terminal 43 amino acids (Figure 2B). It also differs from 
the published sequence at 11 positions, three of which 
occur at third base positions of codons and preserve the 
encoded amino acid sequence. The other eight differ- 
ences lead to changes in amino acid composition (Figure 
2). As these different exons were sequenced repeatedly 
on at least 15 distinct genomes, we are confident that 
the sequence shown in Figure 2 represents an authentic 
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Figure 3. AlignmentsofAminoAcid Sequences 
of the Muscle-Specific Calpains 
The human CANP3 protein is shown on the 
first line. The three muscles-specific se- 
quences (NS, IS1, and IS2) are underlined, and 
the three active site residues are indicated by 
asterisks. The second line corresponds to the 
rat sequence (SwissProt accession number 
P16259). The third and fourth lines show the 
deduced amino acid sequences encoded by 
pig and cow expressed sequence tags (Gen- 
Bank/EMBL accession numbers U05678 and 
U07858, respectively). Amino acids that are 
conserved among all known calpains are 
boxed in black. A period indicates that the 
same amino acid is present in the homologous 
sequence, and letters refer to the variant amino 
acid. Positions of missense mutations are 
given as encircled numbers above the corre- 
sponding amino acid. 
sequence rather than minor polymorphic variants. Further- 
more, these modifications increase the local similarity with 
the rat CANP3 amino acid sequence (Sorimachi et al., 
1989), although the overall similarity is still 94%. 
The ATG numbered 1 in Figure 2B is presumed to be 
the translation initiation site based on homology with the 
rat CANP3 and is within a sequence with five nucleotides 
out of eight in common with the Kosak consensus se- 
quence (Kosak, 1984). Putative CAAT and TATA boxes 
were observed 590 or 324 (CAAT) and 544 or 33 bp (TATA) 
upstream of the initiating ATG codon (Bucher, 1990). PCR 
amplification on muscle cDNA libraries excluded the 
downstream TATA site since it was contained within the 
amplified products (data not shown). A GC-box binding 
the Spl protein (Dynan and Tjian, 1983) was identified at 
position -477. Consensus sequences corresponding to 
potential muscle-specific regulatory elements were identi- 
fied (Figure 2A). These include a myocyte-specific en- 
hancer-binding factor 2 (MEF2)-binding site (Gosset et al. 
1989), a CArG box (serum response elements observed 
in muscle-specific genes and in genes inducible by growth 
hormones; Minty and Kedes, 1986), and four E boxes (con- 
tact sites for basic-helix-loop-helix proteins found in mem- 
bers of the MyoD family; Blackwell and Weintraub, 1990). 
The functional significance of these putative transcription 
factor-binding sites in the regulation of CANP3 gene ex- 
pression remains to be established. 
Two AAUAAA were identified, 520 and 777 bp down- 
stream of the TGA stop codon. The sequencing of a partial 
CANP3 cDNA containing a poly(A) tail demonstrated that 
the first AAUAAA is the polyadenylation signal. The latter 
is embedded in a region well conserved with the rat CANP3 
sequence and is followed after 4 bp by a GT cluster, pres- 
ent in most genes 3' of the polyadenylation site (Birnstiel 
et al., 1985). The 3' untranslated region of the CANP3 
mRNA is 565 bp long. Considering the most likely pro- 
moter location, the predicted length of the cDNA should 
therefore be approximately 3550 bp. 
The DNA and protein sequences of the human CANP3 
gene show high degree of conservation with other calpains 
(Figure 3), in particular at (SwissProt accession numbers 
J05121 and P16259), bovine (GenBank accession num- 
ber U07858), and porcine (GenBank accession number 
U05678) homologous sequences. High local similarities 
between the human and rat DNA sequences are even 
observed at the 5' (75%) or in different parts of the 3' un- 
translated regions (over 60%) (data not shown), sugges- 
tive of evolutionary pressures in their untranslated regions. 
Genomic Organization of the CANP3 Gene 
A comparison of the published CANP3 human cDNA (Sod- 
machi et al., 1989) with the corresponding enomic se- 
quence led to the identification of 24 exons ranging in 
length from 12 bp (exon 13) to 309 bp (exon 1), with a 
mean size of 100 bp (see Figure 1A). The size of introns 
ranges from 86 bp to about 10-16 kb for intron 1. The 
intron-exon boundaries (Table 2) exhibit close adherence 
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Table 2. Sequences at the Intron-Exon Junctions 
Score Score 
Splice Donor Site (%) Intron (%) Splice Acceptor Site Exon 
,CTCCGgtgagt. , .  
,GCTAGgtagga.., 
,TCCAGgtgagg,.,  
,GCTAAgtaagc.. ,  
,TTGATgtaagt . . .  
.CCCGGgtgtgt, . .  
.ATGAGgtaagc...  
.GATAGgtaggt. . .  
.TTCTGgtgagt . . .  
.CCCAGgtggga... 
.ACGAGgtgtgt , . .  
.AAGAGgtatag.. .  
.TCTGAgtgagt . . .  
.CAGTGgtgagt. . .  
.CCAAGgtaggt. . .  
.CACAGgtgtct . . .  
.GAGATgtgagt. . .  
.CAAACgtgagt .. 
.TGGATgtatcc .. 
.GGCAGgtggga .. 
.CGCAGgtgctg .. 
.GTTCAgtaagt .. 
.TGGAGgtaaag .. 
88.5 ~lntron 1~ 99.0 
83.5 ~lntron 2~ 90.0 
92 ~lntron 3-,- 81.5 
82 *-Intron 4~ 81.5 
87 ~lntron 5~ 79.5 
77.5 ~lntron 6~ 91 
94 ~lntron 7-* 78.5 
89 *-Intron 8~ 91.5 
88 ~lntron 9~ 92 
80 *-Intron 10~ 68.5 
85.5 *-Intron 11~ 86 
70 ~lntron 12~ 87 
76.5 ~lntron 13~ 97 
89 -,-Intron 14~ 93,5 
89 ~lntron 15~ 87 
80 ~lntron 16~ 88 
84 ~lntron 17-* 92,5 
83 *-Intron 18~ 90 
56 *-Intron 19~ 88 
80 ,--Intron 20-* 94 
66 ~lntron 21~ 91 
79 "~-Intron 22~ 93.5 
81 ~lntron 23-* 79 
., t t t t tg t t tcacagGAAAT.  
.. gtgtctgcctgcagGGGAC. 
.. acgcttctgtgcagTTCTG.  
.. atcctctctctaagGCTCC.  
.. ccatcgggcctcagGATGG. 
.. t tactgctc tacagACAAT.  
. . . t c tg tgtgct taagGTCCC.  
. . . ca t t t tcccaccagATGGA.  
. t tccaacctctcagGATGT.  
. , t tc tgggggtgcagATACT.  
. . tg t t tc t tc tcaagGTTCC.  
. . tccccatctctcagATGCA.  
. . tgtat tcctcacagGGAAG.  
. . c t t t tc t ta tgcagAAAAA.  
. . cc tcctc tc tccagCCCAT.  
. . t tgtgcctccacagCCACA.  
. . ccct tcctcctcagGACAT.  
. .ctccatccccccagACAAG. 
. .cctccctcctccagACAGA. 
. . t t t tc ta t tgccagAAATA.  
. .ggtcccctccacagGATTC. 
. .gcat tc t t tcacagGAGCT.  
. ,gggact tc t t tcagTGGCT.  
Exon 1 (309 bp) ~ 
Exon 2 (70 bp) ~ 
Exon 3 (119 bp)-* 
Exon 4 (134 bp) ~ 
Exon 5 (169 bp) ~ 
Exon 6 (144 bp) ~ 
Exon 7 (84 bp) -~ 
Exon 8 (86 bp) ~ 
Exon 9 (78 bp) ~ 
Exon 10 (161 bp) ~ 
Exon 11 (170 bp) ~ 
Exon 12 (12 bp) ~ 
Exon 13 (209 bp)-* 
Exon 14 (37 bp)--* 
Exon 15 (18 bp)--* 
Exon 16 (114 bp)-* 
Exon 17 (78 bp)-* 
Exon 18 (58 bp)~ 
Exon 19 (65 bp) ~ 
Exon 20 (69 bp)~ 
Exon 21 (79 bp) ~ 
Exon 22 (117 bp)~ 
Exon 23 (59 bp)~ 
Exon 24 (27 bp)~ 
A score expressing adherence to the consensus was calculated for each size according to Shapiro and Senapathy (1987). Sequences of exons 
and introns are in uppercase and lowercase, respectively. Sizes of exons are given in parenthesis. 
to 5' and 3' splice site consensus sequences (Shapiro and 
Senapathy, 1987). When the genomic sequence was sub- 
mitted to GRAIL analysis (Uberbacher and Mural, 1991), 
11 exons were correctly recognized, four were not identi- 
fied, six were inadequately defined, and two were too small 
to be recognized (data not shown). 
As already noted, the CANP3 gene has three unique 
sequence blocks, NS (amino acid residues 1-61), IS1 (res- 
idues 267-329), and IS2 (residues 578-653). It is interest- 
ing to note that each IS sequence, as well as the nuclear 
translocation signal (residues 595-600) inside IS2, is es- 
sentially flanked by introns (Figure 4). The exon-intron 
organization of the human CANP3 is similar to that re- 
ported for the chicken CANP (the only other large subunit 
calpain gene whose genomic structure is known; Emori 
et al., 1986). 
Four microsatellite sequences were identified (see Fig- 
ure 1A). Two of them are in the distat part of the first intron: 
an (AT)~4 and a previously identified nonpolymorphic 
mixed-pattern microsatellite, D15S498 (Fougerousse et 
al., 1994). A (TA)7(CA)4(GA)~3 was identified in the second 
intron, and genotyping of 64 unrelated Centre d'Etudes 
du Polymorphisme Humain (CEPH) individuals revealed 
two alleles (with frequencies of 0.10 and 0.90). The fourth 
microsatellite is a mixed (CA),(TA)m repeat present in the 
ninth intron. The latter and the (AT),4 repeat have not been 
investigated for polymorphisms. One MER2 repeat and 
14 members of the Alu family were identified in the CANP3 
gene (see Figure 1A), which has, thus, on average one 
Alu element per 2.5 kb. 
Expression of the CANP3 Gene 
The pattern of tissue specificity was investigated by North- 
ern blot hybridization, There is no evidence for the exis- 
tence of an alternatively spliced form of CANP3, although 
A 
Exons met 1 
Inn'on 
positions 
B 
CANP3 protein ~ 
Protein domaln_s I 
Nonsense [B519 
mutations M1394 
[M32 
M2888 
P.27 
Frameshlft B505 
mutations B805 R14 
M 1 8 9 4 _ _  
Splice site IR11,14,~ 
. t I7 1921 23 mutauon [2"26"7 ' ' 
j2131~5 I 617j8'9] 10 j I lt~ 3 t~11561781920212223241 ~11 F F I [Rton
II ]II IV 
cysteine pro~ase domain Ca2+ binding dommn 
(4EF-Hands) 
Rll0X 
tT360X 
945ddG 
2069delCA 
2313delAGAC 
....... 550delA 
• ,946-1 AG-->AA 
2362AG-->TCATCT 
Figure 4. Distribution of the Mutations along CANP3 Protein 
(A) Positions of the 23 introns are indicated by vertical bars. Numbers 
written below refer to the corresponding amino acids. 
(13) Schematic representation of the CANP3 protein, its four domains 
(I, II, Ill, and IV), and muscle-specific sequences (NS, IS1, and IS2). The 
three active site residues are underlined. The positions of missense 
mutations are indicated by dots. The effects of nonsense and 
frameshift mutations are illustrated as truncated lines, representing 
the extent of protein synthesized. The out-of-frame sequence is shown 
by hatched lines. Names of the families carrying these mutations are 
indicated to the left of the lines. 
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Table 3. PCR Primers for the Analysis of the CANP3 Gene 
PCR Product Size Annealing 
(in Base Pa i rs )  Temperature 
Primer Name Primer Sequences (5'-3') Amplified Region (Genomic DNA) (in Celsius) 
CANP3-pro.a TTCAGTACCTCCCGTTCACC Promoter 296 59 
CANP3-pro.m GATGCTTGAGCCAGGAAAAC 
CANP3-exl.a CTTTCCTTGAAGGTAGCTGTAT Exon 1 438 60 
CANP3-exl .m GAGGTGCTGAGTGAGAGGAC 
CANP3-ex2.a ACTCCGTCTCAAAAAAATACCT Exon 2 239 57 
CANP3-ex2.m ATTGTCCCTTTACCTCCTGG 
CANP3-ex3.a TGGAAGTAGGAGAGTGGGCA Exon 3 354 58 
CANP3-ex3.m GGGTAGATGGGTGGGAAGTT 
CANP3.ex4.a GAGGAATGTGGAGGAAGGAC Exon 4 292 59 
CANP3-ex4.m TTCCTGTGAGTGAGGTCTCG 
CANP3-ex5.a GGAACTCTGTGACCCCAAAT Exon 5 325 56 
CANP3-ex5.m TCCTCAAACAAAACATTCGC 
CANP3-ex6.a GTTCCCTACATTCTCCATCG Exon 6 315 57 
CANP3-ex6.m GTTATTTCAACCCAGACCCTT 
CANP3-ex7.a AATGGGTTCTCTGGTTACTGC Exon 7 333 56 
CANP3-ex7.m AGCACGAAAAGCAAAGATAAA 
CANP3-ex8.a GTAAGAGATTTGCCCCCCAG Exon 8 321 58 
CANP3-ex8.m TCTGCGGATCATTGGTTTTG 
CANP3-exg.a CCTTCCCTTCTTCCTGCTTC Exon 9 173 56 
CANP3-ex9.m CTCTCTTCCCCACCCTTACC 
CANP3-exl0.a CCTCCTCACCTGCTCCCATA Exon 10 251 56 
CANP3-exl 0.m TTTTTCGGCTTAGACCCTCC 
CANP3-exl 1 .a TGTGGGGAATAGAAATAAATGG Exon 11 355 57 
CANP3-exl 1 .m CCAGGAGCTCTGTGGGTCA 
CANP3-ex12.a GGCTCCTCATCCTCATTCACA Exon 12 312 61 
CANP3-exl 2.m GTGGAGGAGGGTGAGTGTGC 
CANP3-ex13.a TGTGGCAGGACAGGACGTTC Exon 13 337 60 
CANP3-ex13.m TTCAACCTCTGGAGTGGGCC 
CANP3-ex14.a CACCAGAGCAAACCGTCCAC Exon 14 230 61 
CANP3-ex14.m ACAGCCCAGACTCCCATTCC 
CANP3-ex15.a TTCTCTTCTCCCTTCACCCT Exon 15 225 57 
CANP3-exl 5.m ACACACTTCATGCTCTCTACCC 
CANP3-ex16.a CCGCCTATTCCTTTCCTCTT Exon 16 331 56 
CANP3-exl 6.m GACAAACTCCTGGGAAGCCT 
CANP3-ex17.a ACCTCTGACCCCTGTGAACC Exon 17 270 61 
CANP3-exl 7.m TGTGGATTTGTGTGCTACGC 
CANP3-ex18.a CATAAATAGCACCGACAGGGA Exon 18 258 59 
CANP3-exl 8.m GGGATGGAGAAGAGTGAGGA 
CANP3-ex19.a TCCTCACTCTTCTCCATCCC Exon 19 159 57 
CANP3-ex19.m ACCCTGTATGTTGCCTTGG 
CANP3-ex20.a GGGGATTTTGCTGTGTGCTG Exon 20-21 333 61 
CANP3-ex20.m ATTCCTGCTCCCACCGTCTC 
CANP3-ex22.a CACAGAGTGTCCGAGAGGCA Exon 22 282 57 
CANP3-ex22.m GGAGATTATCAGGTGAGATGCC 
CANP3-ex23.a CAGAGTGTCCGAGAGGCAGGG Exon 22-23 608 61 
CANP3-ex23.m CGTTGACCCCTCCACCTTGA 
CANP3-ex24.a GGGAAAACATGCACCTTCTT Exon 24 375 58 
CANP3-ex24.m TAGGGGGTAAAATGGAGGAG 
CANP3-pA.a ACTAACTCAGTGGAATAGGG Polyadenylation signal 413 56 
CANP3-pA.m GGAGCTAGGATAGCTCAAT 
this cannot be excluded. A transcript of about 3.4-3.6 kb 
was detected in skeletal muscle mRNA (Chiannilkulchai et 
al., 1995). This size therefore further supports the position 
-544  as the functional TATA box. 
Mutation Screening 
CANP3 fulfils both positional and functional criteria to be 
a candidate gene for LGMD2. We therefore systematically 
screened 38 LGMD families for the presence of nucleotide 
changes in CANP3 using a combination of heteroduplex 
(Keen et al., 1991) and direct sequence analyses. 
PCR primers were designed to specifically amplify the 
exons and splice junctions as well as the regions con- 
taining putative CAAT and TATA boxes and the polyade- 
nylation signal (Table 3). PCR products made on DNA of 
LG MD patients were then subjected either to heteroduplex 
analysis or direct sequencing, depending on whether the 
mutation, based on haplotype analysis, was expected to 
be heterozygous or homozygous, respectively. It was oc- 
casionally necessary to clone the PCR products to identify 
the mutations precisely (i.e., for microdeletions or inser- 
tions and for some heterozygotes). Disease-associated 
mutations are summarized in Table 4, and their position 
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Table 4. CANP3 Mutations in LGMD2A Families 
Families Amino 
(R(~union Nucleotide Nucleotide Acid Effect of Restriction Site Protein 
Exon Haplotype) Position Change Position Mutation Change Domain Mutation 
11 
13 
19 
21 
22 
22 
22 
2 B519" 328 CGA~TGA 110 
4 M42 545 CTG~CAG 182 
4 M1394, M2888 550 C~tu~-*CA 184 
5 M35, M37 701 GGG~GAG 234 
6 M32 945 CGG--*CG 315 
6-7 Rl1", R14, R16", R17, R19", 946-1 G~A 
R21", R26", R27 (I, II) 
8 M2407" 1061 GTG-*GGG 354 
8 M 1394 1079 TGG-*TAG 360 
M2888 1468 CGG--*TGG 490 
R12" (VII) 1715 CGG~CCAG 572 
R27 (VIII) 2069-2070 Deletion AC 690 
R14, R17 (111) 2230 AGC--*GGC 744 
A*, B501", M32 2306 CGG--*CAG 769 
B505 2313-2316 Deletion AGAC 771-772 
B505, R14 (IV) 2362-2363 AG~TCATCT 788 
Arg~stop -- II R110X 
Leu~GIn - II L182Q 
Frameshift -- II 550AA 
Gly-*Glu - II G234E 
Frameshift Without Smal II 945AG 
Abberant -- II 946-1 G--*A 
splicing 
Val~Gly - II V354G 
Trp-*stop Without Bstnl, II T360X 
without EcoRI, 
without Scrfl 
Arg--*Trp III R490T 
Arg-*GIn Without Mspl Ill R572Q 
Frameshift IV 2069ACA 
Ser-*Gly Without Alul IV $744G 
Arg-*GIn -- IV R769Q 
Frameshift -- IV 2313AAGAC 
Frameshift -- IV 2362AG~TCATCT 
The first letter of the family code refers to the origin of the population (B, Brazil; M, metropolitan France; R, Isle of La R6union; A, Amish; the 
corresponding haplotypes for La R6union island families are numbered in parentheses). Families that are homozygous for mutation are indicated 
by asterisks. Positions are numbered on the basis of the cDNA and protein sequences starting from ATG and the first methionine residue, 
respectively. The mutated nucleotides are underlined. 
along the protein is shown in Figure 4. Each mutation was 
confirmed by heteroduplex analysis, sequencing of both 
strands in several members of the family or enzymatic 
digestion when the mutation modified a restriction site. 
Segregation analyses of the mutations, performed on 
DNAs from all available members of the families, con- 
firmed that these sequence variations are on parental 
chromosomes carrying a LGMD2A mutation. To assess 
the possibility that missense substitutions might be poly- 
morphisms, their presence was systematical ly tested in a 
control population: none of the mutations was seen among 
120 control chromosomes from the CEPH reference fam- 
ilies. 
Chromosome 15 Ascertained Families 
The initial screening for causative mutations was per- 
formed on families from the La R6union island (Beckmann 
et al., 1991), from the Old Order Amish of northern Indiana 
(Young et al., 1992), and from Brazil (Passos-Bueno et 
al., 1993). 
La R~union Island Families 
Genealogical  studies and the geographic origin of the fam- 
ilies from La R6union were suggestive of a single founder 
effect. Genetic analyses are, however, inconsistent with 
this hypothesis as the families present haplotype hetero- 
geneity, with at least six different carrier chromosomes 
(Allamand et al., 1995b). In the course of this work, distinct 
mutations corresponding to six haplotypes have been 
identified (Table 4). Yet these mutations are absent in 
some of the minor haplotypes. Thus, some of them must 
still contain at least one other unidentif ied mutation. 
In family R14, exons 13, 21, and 22 showed evidence 
for sequence variation upon heteroduplex analysis (Figu re 
5). Sequencing of the associated PCR products revealed 
a polymorphism in exon 13, a A--*G mutation in exon 21 
transforming Ser-744 to glycine in the second EF hand 
(see Figure 4), and a AG-*TCATCT frameshift mutation 
in exon 22 causing premature termination at nucleotide 
2400 where an in-frame stop codon occurs (see Figure 
4). The exon 21 mutation and the polymorphism in exon 
13 form an haplotype that is also encountered in family 
R17. 
Affected individuals in family R12 are homozygous over 
the entire LGMD2A interval (Allamand et al., 1995b). Se- 
quencing of the PCR products of exon 13 revealed a G---A 
transition at base 1715 of the cDNA resulting in a substitu- 
tion of glutamine for Arg-572 (Figure 6) inside domain Ill, 
a residue that is highly conserved throughout all known 
calpains. This mutation, detectable by loss of an Mspl 
restriction site, is present only in this family and in no other 
examined LGMD2A families or unrelated controls (data 
not shown). 
In family R27, heteroduplex analysis fol lowed by se- 
i~t  i l l  
E4  E5  E6  E8  E l i  E l9  E2 I  E22  
Figure 5. Representative Mutations Identified by Heteroduplex 
Analysis 
Examples of mutations detected by heteroduplex analysis. Lanes C 
represent control samples. Exon numbers (E) are indicated below the 
gels. Pedigree B505 displays the segregation of two different muta- 
tions in exon 22. 
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A EXON 2 
AATCCCCGAT T TA  
A iilVVVl ,,', 
Normal [,i .i^ l li~ lli~,"~ M 
sequence/~Y,.,I~_ .."~ ~.~"i~"'_ i~ 
AATCCCTGATTTA 
CGA -> TGA 
Arg110 Stop 
B EXONS 
AGCTGGTGCGGCT 
i i  ~ J, , i i  i i  Normal 
AGCTGGGGCGGC T 
GTG -> GGG 
Va1354 Gly 
C EXON 13 D EXON 22 
CCATGCG GTACGC 
sequence :'~ ,. r. 11 /i 
t:~AV i; . . . .  ~,.., 
CCATGCAGTACGC 
,Jtv]',:i 
CGG -> CAG 
Arg769 Gin 
CCATGCAGTACGC 
CGG -> CAG 
Arg769 Gin 
Figure 6. Sequence of Homozygous Mutations 
Sequences from a healthy control are shown above the mutant se- 
quences present in axons 2 (A), 8 (B), 13 (C), and 22 (D). Asterisks 
indicate the position of mutated nucleotides. The consequences on 
codon and amino acid residues are indicated at the left of each panel 
together with the name of the family. 
TCCTCCGGGTC TT  
~ i i , ?. . 
Normal ,.,, a i! :: ~: ! r 
sequence I ~ i~ ~ i~-'~ I~,'~ 
TCCTCCAGGTCTT 
CGG -> CAG 
Arg572 Gln 
quencing of the PCR products of an affected child revealed 
a 2 bp deletion in exon 19 (see Figure 5; Table 4). One 
AC out of three is missing at this position of the sequence, 
producing a stop codon at position 2069 of the cDNA se- 
quence (see Figure 4). 
Since both mutation detection enhancer heteroduplex 
analysis and direct sequencing failed to reveal the muta- 
tions in the two major haplotypes (I and II), an attempt was 
made to uncover aberrant splicing of the muscle-specifi c 
calpain mRNA from these patients by taking advantage 
of the illegitimate transcription in lymphocytes (Chelly et 
al., 1989). The PCR products corresponding to exons 3-9 
showed the presence of a band about 400 bases longer 
than expected. Fine PCR mapping localized the mutation 
at the junction of exons 6 and 7, while sequencing of the 
corresponding products (Figure 7) revealed an acceptor 
splice site mutation (AG~AA), resulting in the utilization 
of an alternative site within intron 6, 391 bp upstream of 
exon 7. The same mutation was seen in haplotypes I and 
II (Table 4), even though they differ in 14 out of 28 markers. 
It is still unclear whether these are related to one another 
or a coincidence of two independent recurrent mutational 
Normal  cDNA sequence 
exon6 / exon7 
/ 
ProThr  Arg [Fhr Ile lie 
CO3/~CCGOACAATCATT 
Splice site mutat ion 
exon 6 < 391 bo -~ exon 7 
Pro Thr Arg IGlu Stop *l 
CCGACCCGOGAATAG CTACAAtACAATCAT T 
. :~: I / 
Figure 7. Sequence Analysis of the Junction between Exons 6 and 
7 of CANP3 of Illegitimately Transcribed mRNAs 
The corresponding sequence from a normal muscular CANP3 cDNA 
(above) or from a LG MD2A patient (below) are shown, together with the 
corresponding amino acids. The asterisk indicates the G~A transition 
responsible for the loss of the normal acceptor site leading to the use 
of a cryptic splice site within intron 6. This aberrant splicing results 
in the presence in the mRNA of an additional 391 bp intronic sequence, 
represented by an arrow, and of a stop codon as indicated above the 
sequence. 
events. The presence of these mutations was confirmed 
on genomic DNA. The net result is presumably the loss 
of CANP3 activity since they lead to premature termination 
by a stop codon that is adjacent to the aberrant splice site 
(Figure 7). 
Amish Families 
As expected, owing to multiple consanguineous links, the 
examined northern Indiana Amish LGMD2A patients were 
homozygous for the carrier hapiotype (Allamand et al., 
1995b). A G~A missense mutation was identified at nucle- 
otide 2306 within exon 22 (see Figure 6), transforming 
Arg-769 to glutamine. This residue, which is conserved 
throughout all members of the calpain family in all species, 
is located in domain IV of the protein within the third EF 
hand at the helix-loop junction (see Figure 4). This muta- 
tion was encountered in a homozygous tate in all patients 
from 10 chromosome 15-1inked Amish families. We also 
verified that this nucleotide change was not present in 
patients from the six southern Indiana Amish LGMD fami- 
lies for which the chromosome 15 locus was excluded by 
linkage analyses (Allamand et ai., 1995a), thus confirming 
the genetic heterogeneity of this disease in this genetically 
related isolate. 
Brazilian Families 
As a result of consanguineous marriages, two Brazilian 
families (B501 and B519) are homozygous for extended 
LGMD2A carrier haplotypes (Allamand et al., 1995b). Af- 
fected individuals from family B501 were shown to have 
the same exon 22 mutation as the Amish LGMD2A pa- 
tients (see Figure 6), but embedded in a completely differ- 
ent haplotype (Allamand et al., 1995b). In family B519, the 
patients carry a C~T transition in exon 2 in a homozygous 
Mutations in CANP3 Cause LGMD2A 
35 
Table 5. CANP3 Polymorphisms 
Amino Acid Restriction Site 
Location Families Nucleotide Position Nucleotide Change Position Change 
Promoter M42 -408 T~C -- -- 
1 M31 96 ACT~ACC 32 Ddel~Secl 
3 M37, M4O 495 TTC~TTT 165 Without Mboll 
13 R14, R17 1668 ATC~ATT 556 -- 
Intron 22 Rll, R19, R20, M35, M37 2380 + 12 Deletion A -- -- 
See Table 4 legend for details. 
state, replacing Arg-328 with a TGA stop codon (see Fig- 
ure 6), thus presumably leading to a very truncated and 
inactive protein (see Figure 4). 
Analysis of Other LGMD Families 
Having validated the role of CANP3 in the chromosome 15 
ascertained families, we next examined by heteroduplex 
analysis LGMD families for which linkage data were not 
informative. These included one Brazilian (B505) and 10 
metropolitan French pedigrees. Additional mutations were 
uncovered enabling the ascertainment of eight more 
LGMD2A families. 
Heteroduplex bands were revealed for exons 1,3, 4, 5, 
6, 8, 11, 22, and the promoter region of one or more pa- 
tients (see Figure 5). Of all sequence variants, 10 were 
identified as pathogenic mutations (five missense, one 
nonsense, and four frameshift mutations) and four as poly- 
morphisms. Altogether, two morbid alleles were identified 
in five families, one in three, and none in three others 
(Table 4). Identical mutations were uncovered in appar- 
ently unrelated families. The mutations hared by families 
M35 and M37 or by M2888 and M1394, respectively, are 
likely to be the consequence of independent events since 
they are embedded in different marker haplotypes. In con- 
trast, it is likely that the point mutation present in exon 
22 of the Amish and in the M32 kindreds corresponds to 
the same mutational event, as both chromosomes share 
a common four-marker haplotype (D15S779-D15S512- 
D15S782-D15S780) around CANP3 (unpublished data), 
possibly reflecting a common ancestor. The same holds 
true for the exon 22 substitution shared by families B505 
and R14. 
In addition to the polymorphisms present in exon 13 in 
families R14 and R17 (position 1668) and in the intragenic 
microsatellites, four additional neutral variations were de- 
tected (Table 5). 
Discussion 
Several lines of evidence implicate the CANP3 gene in 
the etiology of LGMD2A. This gene is localized inside the 
3 Mb LGMD2A interval, in the region suggested by linkage 
disequilibrium studies (Allamand et al., 1995b). Southern 
blot experiments (Ohno et al., 1989) and sequence-tagged 
site screening (data not shown) suggest that there is but 
one copy per genome of this member of the calpain family. 
Transcription studies suggested that it is an active gene 
rather than a pseudogene, and its muscle-specific pattern 
of expression is consistent with the phenotype of this disor- 
der (Sorimachi et al., 1989; Chiannilkulchai et al., 1995). 
A minimum of 17 independent mutational events were 
identified in families from different ethnic and geographic 
groups. These represent 15 different mutations, distrib- 
uted throughout the gene (Figure 4), that cosegregate with 
the disease in LGMD2A families. The discovery of two 
nonsense, one splice site, and five frameshift mutations 
in CANP3 supports the hypothesis that a deficiency of this 
gene product causes LGMD2A. All eight mutations result 
in a premature in-frame stop codon, leading to the produc- 
tion of truncated and presumably inactive proteins (Figure 
4). Evidence for the morbidity of the missense mutations 
come from several sources: their relative high incidence 
among LGMD2A patients, the failure to observe these mu- 
tations in control chromosomes, and the occurrence of 
mutations at evolutionarily conserved residues, in regions 
of documented functional importance, or both (Sorimachi 
et al., 1989). Of seven mutations, four change an amino 
acid that is conserved in all known members of the calpain 
family in all species (Figure 3). Two of the remaining muta- 
tions affect less conserved amino acid residues, but are 
located in important functional domains: V354G is four 
residues before the asparagine at the active site; $744G 
within the second EF hand may impair the calcium- 
dependent regulation of calpain activity or the interaction 
with a small subunit (Figure 4). Several missense muta- 
tions change a hydrophobic residue to a polar one or vice 
versa (Table 4), possibly disrupting higher order struc- 
tures. 
The R6union Paradox 
Only four different mutations were identified by hetero- 
duplex and sequence analyses in the families of La R~- 
union, despite the fact that all exons were scanned. Even- 
tually, the use of illegitimate transcription allowed us to 
uncover aberrant splicing, leading to the recognition of 
the same splice site mutation in haplotypes I and II (Table 
4). Thus, five different mutations have been identified so 
far in this population. But given that none of them was 
found on the remaining carrier haplotypes, there should 
be at least one other (as yet unidentified) mutation. 
The presence of at least six different mutations among 
patients from the La R~union island demonstrates the va- 
lidity of the suggestion based on haplotype analysis of a 
multifounder effect (AIlamand et al., 1995b). This is, how- 
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ever, an unexpected result given the multiple consanguin- 
eous links in these families. Indeed, the affected patients 
of La R~union all belong to a small genetic isolate, pre- 
sumed to derive from a single ancestor who immigrated 
to this island in the 1670s. These patients were all thus 
expected to carry the same LGMD2A mutation. The occur- 
rence of multiple independent events in other small popu- 
lations is not unprecedented (e.g., Bach et al., 1994; Rod- 
ius et al., 1994; Heinisch et al., 1995), although no 
satisfactory explanation has been forwarded so far. 
Thus, the presence of multiple mutations in the La R~- 
union population eeds to be reconciled with the reported 
low prevalence of this disease, a problem we refer to as 
the R~union paradox. 
To begin, the global prevalence of LGMD2A could just 
be much more common than initially presumed, but this 
seems highly unlikely. Another hypothesis assumes that 
heterozygous healthy individuals could benefit from a se- 
lective advantage (as in 13-thalassemia), resulting in a high 
local prevalence. This hypothesis, however, seems also 
unlikely since one would not expect such selective pres- 
sures to lead to these results in such a limited timespan 
(i.e., 320 years at most). 
We therefore speculate that this condition, which has 
this far been considered as a monogenic disorder, may 
reflect a more complex inheritance pattern, in which ex- 
pression of the calpain mutations would be dependent on 
genetic background (nuclear or mitochondrial). Consider, 
for instance, a digenic model: only in the presence of spe- 
cific alleles at a permissive second unlinked locus (e.g., a 
compensatory, partially redundant, regulatory, or modifier 
gene) will there be expression of calpain mutations. Since 
one would need mutations at both loci to be affected, the 
disease prevalence would remain low. Under this model, 
members of the La R~union island community would, as 
a result of genetic drift, have a disease-associated allele 
at the hypothesized second locus at high frequency (or 
even fixed in this small population), conditions that would 
explain the apparent complete penetrance of the calpain 
mutations. The complete penetrance of this disease in 
the Amish and in the other described LGMD2A pedigrees 
would also be under control of the second locus. 
If this model is true, there may be fewer selective pres- 
sures against the appearance of CANP3 mutations, as a 
result of the conditional penetrance. In other words, the 
frequency of the calpain variants in the overall population 
can be much higher than initially deduced, based on the 
estimates of the prevalence of the disease under a simple 
monogenic model. Assume, for instance, recessive, inde- 
pendent, and fully penetrant expression at two autosomal 
loci, with similar frequencies for both deleterious alleles. 
Considering the reported prevalence (10-5; Emery, 1991) 
and the estimated genetic heterogeneity, 1 in 25 persons 
would be a carrier for a deleterious calpain allele (and 1 
in 625 would carry deleterious alleles at both loci). The 
frequency of calpain variants could thus approach that of 
the cystic fibrosis gene. If we assume the allele frequency 
at the second locus to be, respectively, 0.1 or 0.2, this 
would give us one LGMD2A carrier per 58 or 116 individu- 
als. But, since expression of the trait would require the 
simultaneous presence of both sets of deleterious alleles, 
the overall prevalence remains, as expected, on the order 
of 10 -~. 
Under this model, some of the families for which the 
role of the LGMD2A locus was previously excluded, based 
on linkage analyses assuming simple monogenic inheri- 
tance, might be authentic LGMD2A families, reflecting dif- 
ferential segregation of these two unlinked genes. The 
digenic inheritance model th us predicts that in a number of 
kindreds, there will be healthy individuals with two mutant 
calpain genes. To test the validity of this model, we are 
currently performing a systematic screening for the pres- 
ence of calpain mutations in DNA from affected probands 
from all small nuclear families that cannot be identified as 
LGMD2A on the basis of linkage analyses. We will then 
assess the cosegregation of the mutations in these pedi- 
grees, searching for asymptomatic arriers of two mutant 
calpain genes. 
An alternative possibility assumes that the calpain muta- 
tions are pathogenic only in a specific mitochondrial con- 
text. It is worthwhile remembering that the mitochondria 
are central suppliers of energy and could therefore influ- 
ence the fate of muscle cells. The mitochondrial model 
predicts a monogenic inheritance pattern within nuclear 
families (all sibs share the same mitochondrial genome). 
In other pedigrees, however, we should fail to get expres- 
sion of the disease in individuals carrying calpain muta- 
tions in a nonpermissive mitochondrial genetic back- 
ground. 
It is important o stress that the observations in favor of 
the proposed departure from simple monogenic inheri- 
tance are not unprecedented. There has been the report 
of digenic inheritance of retinitis pigmentosa (Kajiwara et 
al., 1994). And there are a number of additional descrip- 
tions of traits for which expression is clearly influenced 
by the presence of unlinked mutations (e.g., Oppenheim 
et al., 1990). 
The concomitant involvement of two or more loci in the 
LGMD2A phenotype may have some immediate practical 
consequences. Since the current estimates for genetic 
heterogeneity are based on a simple monogenic model, 
these would be truly inadequate under digenic or more 
complex inheritance models. In addition, if one of the latter 
turns out to be true, its impact on genetic counseling will 
also need to be carefully evaluated. 
Clearly, the mechanism underlying the results reported 
here may have major bearing on our comprehension of 
simple genetic traits. They may imply that one may occa- 
sionally face similar situations in other inbred human popu- 
lations, such as Finland. The proposed di- or oligogenic 
model could also explain some of the failures to reproduce 
known or expected human phenotypes in mouse gene 
knockout experiments, since the genetic backgrounds 
allowing for expression of the corresponding traits may not 
have been present. One particularly convincing example 
is the work of Rudnicki et al. (1993) on MyoD and Myf-5 
transgenic mice, where only double knockout animals ex- 
press a pathological phenotype. Another example are the 
Igfl knockouts, which show variable survival rates de- 
pending on the genetic background (Liu et al., 1993). One 
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prediction of this model is that the mouse CANP3 knock- 
outs may also fail to have a pathological phenotype. 
CANP3 and LGMD2A 
Identification of CANP3 as a defective gene in LGMD2A 
suggests a novel pathological mechanism leading to a 
muscular dystrophy in which this condition is caused by 
mutations affecting an enzyme and not a structural com- 
ponent of muscle tissue. This result is to be contrasted with 
all known other muscular dystrophies, such as Duchenne 
and Becker (Bonilla et al., 1988), severe childhood autoso- 
real recessive (M atsumara et al., 1992), Fu kuyama (Matsu- 
mara et al., 1993), merosin-deficient congenital muscular 
dystrophies (Tom~ et al., 1994), and primary adhalin defi- 
ciencies (Roberds et al., 1994). 
The understanding of the LGMD2A phenotype needs to 
take into account the fact that there is likely to be no active 
CANP3 protein in several patients, a loss compatible with 
the recessive manifestation of this disease. Simple models 
in which this protease would be involved in the degradation 
or destabilization of structural components of the cytoskel- 
eton, extracellular matrix, or dystrophin complex must 
therefore be ruled out. Furthermore, there are no signs 
of such alterations by immunohistochemical studies on 
LGMD2 muscle biopsies (Matsumara et al., 1993; Tome 
et al., 1994). Likewise, since LGMD2A myofibers are ap- 
parently not different from others that are dystrophic, it 
seems unlikely that this calpain plays a role in myoblast 
fusion, as proposed for ubiquitous calpains (Wang et al., 
1989). 
Alternative hypotheses must therefore be forwarded. 
One could imagine that the CANP3 participates in the acti- 
vation of an enzyme or other protein involved in muscle 
metabolism, or it could be responsible for the catabolism 
of protein compounds in the muscle; the absence of such 
activity would result in a toxic accumulation of these com- 
pounds and eventually in the degeneration of muscle fi- 
bers. We favor another hypothesis wherein the CANP3 
protein plays an active role in transduction of a signal, a 
hypothesis that takes the previously described properties 
of the ubiquitous calpain and of CANP3 into account. 
Indeed, studies of CANP3 expression (Sorimachi et al., 
1993b) reported that its mRNA is abundant (its expression 
being 10-fold higher than that of the ubiquitous calpains) 
and specific to fully differentiated myotubes and myofi- 
bers. Yet attempts to detect this protein failed (Sorimachi 
et al., 1993b). This is interpreted as a consequence of 
its extremely rapid turnover mediated by autocatalysis, 
possibly reflecting the need for precise regulation of its 
activity. When the CANP3 protein was expressed and 
measured in transfected COS and L8 myoblast cells, it 
was shown to have a nuclear localization (Sorimachi et 
al., 1993b), possibly mediated by the nuclear translocation 
signal in the IS2 region. This result suggests that this cellu- 
lar compartment could be its natural site of action. The 
calpains have been proposed as having regulatory rather 
than degradative role, mediated by restricted proteolysis 
of specific proteins (Wang et al., 1989; Suzuki and Ohno, 
1990; Croall and Demartino, 1991). In fact, ubiquitous cal- 
pains have been reported to regulate transcription by spe- 
cific cleavage of c-Jun and c-Fos (Hirai et al., 1991) and 
by controlling NF-~<B activities through proteolysis of its 
IKB-~ inhibitor (Miyamoto et al., 1994). These reports sug- 
gest that CANP3 protein could be also involved in the 
control of gene expression by regulating the turnover or 
activity of transcription factors or of their inhibitors (e.g., 
members of the Id family; Benezra et al., 1990). 
The finding that a defective calpain underlies the patho- 
genesis of LGMD2A may prove useful for the identification 
of other loci involved in neuromuscular diseases. Other 
forms of LGMD may indeed be caused by mutations in 
genes whose products are calpain substrates or in genes 
involved in the regulation of CANP3 expression. Tech- 
niques such as the two-hybrid selection system (Fields 
and Song, 1989) could lend themselves to the isolation of 
the natural protein substrate(s) of this calpain and thus 
potentially help to identify candidate loci. These ap- 
proaches, inasmuch as they will lead to the identification 
of the other partners responsible for the LG MD phenotype, 
could eventually also clarify the molecular genetic basis 
of the inheritance pattern of LGMD2A. 
With the caveat of the as-yet-unclarified inheritance 
mode, identification of mutations in the CANP3 gene could 
provide means for direct prenatal or presymptomatic diag- 
nosis and carrier detection in families in which both muta- 
tions have been identified. Gene-based classification of 
LGMD2A families should prove useful for the differential 
diagnosis of this disorder and for the establishment of phe- 
notype-genotype relationships. The fact that morbidity re- 
sults from the loss of an enzymatic activity raises hopes 
for novel pharmacotherapeutic prospects for this neuro- 
muscular disorder or other myopathies. Finally, the evi- 
dence of pathological consequences of loss of a tissue- 
specific proteolytic activity, having a possible regulatory 
role, suggests that this may be a process of general signifi- 
cance. 
Experimental Procedures 
Description of the Patients 
The LGMD2A families analyzed included three Brazilian families 
(Passos-Bueno et al., 1993), 10 interrelated nuclear families from La 
Reunion (Beckmann et al., 1991), 10 French metropolitan families, 
and 10 Amish families (Jackson and Carey, 1961). The majority of 
these families were previously ascertained by linkage analysis to be- 
long to the chromosome 15 group (Beckmann et al., 1991; Young et 
al., 1992; Passos-Bueno et al., 1993). However, some families from 
metropolitan France, as well as one Brazilian family (B505), had insig- 
nificant Iod scores (less than 3.0) for chromosome 15. 
Sequencing of Cosmid c774G4-1F11 and EcoRI Restriction 
Map of Cosmids 
Cosmid 1Fll (Figure 1C) was subcloned and sequenced following 
conventional procedures. The sequences were analyzed and align- 
ments performed using the XBAP software of the Staden package, 
version 93.9 (Staden, 1982). Gaps between sequence contigs were 
filled by walking with internal primers. EcoRI restriction map of cosm ids 
was performed essentially as described in Sambrook et al. (1989). 
Analysis of CANP3 in LGMD2A Patients 
Human DNA (100 ng), obtained from peripheral blood lymphocytes, 
was used per PCR (Fougerousse t al., 1994; Table 3). Heteroduplex 
analyses were performed on 10 p.I of PCR products essentially as in 
Keen et al. (1991). For sequence analysis, the PCR products were 
subjected to dye-dideoxy sequencing, after purification through Micro- 
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Table 6. PCR Primers for the Illegitimate Transcription of the CANP3 Gene 
PCR Product Size Annealing 
Position within on cDNA Temperature 
Primer Name Primer Sequence (5'--3') the cDNA (in Base Pairs) (in Celsius) 
CANP3-Ala CAGCTCGGTTTTTAAGATGG -188 to -169 674 57 
CANP3-A1 m CGTCCACCCACTCTCCATAG 507-527 
CANP3-Bla AAGTTCCCCATCCAGTTCGT 274-293 1006 57 
CANP3-B1 m GAAGCTTGTCAGACTGCAGA 1260-1279 ,, 
CANP3-C1 a GTCACGCCTACTCTGTCACG 998-1017 912 57 
CANP3-C1 m GCTTTTGCTTATCAGGGCTT 188-1903 
CAN P3-D1 a TTGAAAATACCATCTCCGTG 1751-1770 869 57 
CANP3-D1 m GGGGTAAAATGGAGGAGGAA 2590-2619 
CANP3-A2a CTTTCCTTGAAGGTAGCTGTAT -63 to -42 548 57 
CANP3-A2m AAGATCCCTGCGTAGTTTTCG 468-488 
CANP3-B2a ATGGAGCCAACAGAACTGAC 341-360 914 57 
CANP3-B2m GGCCGTGAGGTTGCAGATCT 1235-1254 
CANP3-C2a AGGTGGAGTGGAACGGTTCT 1085-1103 760 57 
CANP3-C2m GCTCCTTGTTGCTGTTTGCT 1824-1843 
CANP3-D2a CCATCATCTTCGTTTCGGAC 1792-1811 721 57 
CAN P3-D2m GGGTGAAACTGAAATCCTGA 2503-2522 
con devices (Amicon). When necessary, depending on the nature of 
the mutations (e.g., frameshift mutation or for some heterozygotes), 
the PCR products were cloned using the TA cloning kit from Invitrogen. 
Total cellular RNA was extracted from lymphoblastoid cell lines by 
the RNAzol method (Bioprobe Systems). Reverse transcription was 
performed under standard conditions using 1 p_g of RNA in a total 
volume of 30 p~l containing 20 U of RNasin (Promega) and 200 U of 
Superscript reverse transcriptase (Bethesda Research Laboratories), 
We performed 20 cycles of PCR (40 s at 92°C, 30 s at 57°C, and 1 
min at 72°C) on 1 p.I of the cDNA sample using one of four sets of 
primers (A1, B1, C1, and D1; Table 6) to obtain four overlapping frag- 
ments spanning the whole CANP3 coding sequence. The PCR product 
(1 pl) was then subjected to a second round of PCR amplification using 
nested primers (A2, B2, C2, and D2; Table 6). The PCR amplification 
products were analyzed by agarose gel electrophoresis and by direct 
double-stranded DNA sequencing. 
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